Misoprostol (Cytotec)

ISSN 0256-5004 (Print)

AIMS Journal Vol 13 No 3

IMPORTANT DRUG WARNING CONCERNING UNAPPROVED USE OF INTRAVAGINAL OR ORAL MISOPROSTOL IN PREGNANT WOMEN FOR INDUCTION OR LABOR OR ABORTION

August 23, 2000
Re: Cytotec (misoprostol)

Dear Health Care Practitioner:

The purpose of this letter is to remind you that Cytotec administration by any route is contraindicated in women who are pregnant because it can cause abortion. Cytotec is not approved for the induction of labor or abortion.

Cytotec is indicated for the prevention of NSAID (nonsteroidal anti- inflammatory drugs, including aspirin) - induced gastric ulcers in patients at high risk of complications from gastric ulcer, eg the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer.

The uterotonic effect of cytotec is an inherent property of prostaglandin E1 (PGE1), of which Cytotec is a stable, orally active, synthetic analog. Searle has become aware of some instances where Cytotec, outside of its approved indication, was used as a cervical ripening agent prior to termination of pregnancy, or for induction of labor, in spite of the specific contraindications to its use during pregnancy.

Serious adverse events reported following off-label use of Cytotec in pregnant women include maternal or fetal death; uterine hyperstimulation, rupture or perforation requiring uterine surgical repair, hysterectomy or salpingo-oophorectomy, amniotic fluid embolism, severe vaginal bleeding, retained placenta, shock, fetal bradycardia and pelvic pain.

Searle has not conducted research concerning the use of Cytotec for cervical ripening prior to termination of pregnancy or for induction of labor, nor does Searle intend to study or support these uses. Therefore, Searle is unable to provide risk information for Cytotec when it is used for such purposes. In addition to the known and unknown acute risks to the mother and fetus, the effect of Cytotecon the later growth, development and functional maturation of the child when Cytotec is used for induction of labor or cervical ripening has not been established.

Searle promotes the use of Cytotec only for its approved indication. Please read the enclosed updated complete Prescribing Information for Cytotec.

Further information may be obtained by calling 1-800-323-4204.

Michael Cullen MD
Medical Director, US
Searle


The AIMS Journal spearheads discussions about change and development in the maternity services..

AIMS Journal articles on the website go back to 1960, offering an important historical record of maternity issues over the past 60 years. Please check the date of the article because the situation that it discusses may have changed since it was published. We are also very aware that the language used in many articles may not be the language that AIMS would use today.

To contact the editors, please email: journal@aims.org.uk

We make the AIMS Journal freely available so that as many people as possible can benefit from the articles. If you found this article interesting please consider supporting us by becoming an AIMS member or making a donation. We are a small charity that accepts no commercial sponsorship, in order to preserve our reputation for providing impartial, evidence-based information.

JOIN AIMS

MAKE A DONATION

Buy AIMS a Coffee with Ko-Fi

AIMS supports all maternity service users to navigate the system as it exists, and campaigns for a system which truly meets the needs of all.

Latest Content

Journal

« »

Issues of trust led to me becoming…

AIMS Journal, 2024, Vol 36, No 3 By Ryan Jones This is a journal article about trust, and it’s also a journal article about my journey to becoming a volunteer at AIMS. I…

Read more

I trust we can change

AIMS Journal, 2024, Vol 36, No 3 By Claire Dunn I found myself sitting in the waiting room of a prestigious hospital in West London pondering what lay ahead, for I was on…

Read more

Editorial - Trust and responsibilit…

AIMS Journal, 2024, Vol 36, No 3 By Alex Smith Welcome to the September 2024 issue of the AIMS journal. The theme for this quarter explores different aspects of trust enc…

Read more

Events

« »

AIMS AGM

AIMS AGM 2024 All members welcome to join us in Birmingham or online - further details to follow in AIMS Members Mailing Please email admin@aims.org.uk if you plan to att…

Read more

Accessing Care and Treatment with D…

Join Dr Rebecca Moore for an overview of the kinds of treatments and support available after birth trauma and how to access them. https://traininghub.makebirthbetter.org/…

Read more

The National Maternity Safety Confe…

Fifth annual National Maternity Safety Conference https://www.eventbrite.co.uk/e/the-national-maternity-safety-conference-2024-tickets-788035283747

Read more

Latest Campaigns

« »

AIMS Letter to Wes Streeting

AIMS has written to Wes Streeting MP, welcoming him to the role of Secretary of State for Health and Social Care. We acknowledge his awareness that maternity services are…

Read more

Involving Service User Voices in Ma…

This is an edited version of an invited talk given by Jo Dagustun, AIMS Campaigns Team, to the International Labour and Birth Research Conference UK, 24 - 26 April 2023.…

Read more

Birth Trauma Inquiry Open Letter in…

We write this letter in response to the recently published APPG Report on Birth Trauma which can be found here The report was extremely moving and we honour the brave con…

Read more